Intercept Pharmaceuticals Inc (ICPT) Stake Lifted by Bank of Montreal Can

Bank of Montreal Can lifted its stake in shares of Intercept Pharmaceuticals Inc (NASDAQ:ICPT) by 15.2% during the 4th quarter, HoldingsChannel.com reports. The fund owned 14,240 shares of the biopharmaceutical company’s stock after acquiring an additional 1,877 shares during the period. Bank of Montreal Can’s holdings in Intercept Pharmaceuticals were worth $1,435,000 at the end of the most recent quarter.

Several other hedge funds also recently made changes to their positions in the company. Virtus ETF Advisers LLC lifted its holdings in shares of Intercept Pharmaceuticals by 7.2% during the 3rd quarter. Virtus ETF Advisers LLC now owns 9,618 shares of the biopharmaceutical company’s stock worth $1,215,000 after acquiring an additional 648 shares during the period. Swiss National Bank raised its holdings in Intercept Pharmaceuticals by 2.3% in the third quarter. Swiss National Bank now owns 36,100 shares of the biopharmaceutical company’s stock valued at $4,562,000 after buying an additional 800 shares during the period. Strs Ohio purchased a new position in Intercept Pharmaceuticals in the third quarter valued at approximately $126,000. Teachers Advisors LLC raised its holdings in Intercept Pharmaceuticals by 3.0% in the third quarter. Teachers Advisors LLC now owns 43,018 shares of the biopharmaceutical company’s stock valued at $5,436,000 after buying an additional 1,254 shares during the period. Finally, Chicago Equity Partners LLC purchased a new position in Intercept Pharmaceuticals in the third quarter valued at approximately $215,000. Institutional investors and hedge funds own 63.48% of the company’s stock.

ICPT has been the topic of several research reports. BidaskClub lowered shares of Intercept Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday, October 19th. Needham & Company LLC restated a “hold” rating on shares of Intercept Pharmaceuticals in a report on Wednesday, October 31st. Oppenheimer set a $100.00 price target on shares of Intercept Pharmaceuticals and gave the company a “hold” rating in a report on Wednesday, October 31st. Wedbush set a $220.00 price target on shares of Intercept Pharmaceuticals and gave the company a “buy” rating in a report on Tuesday, November 6th. Finally, ValuEngine lowered shares of Intercept Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Monday, November 12th. Three equities research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the stock. Intercept Pharmaceuticals presently has a consensus rating of “Buy” and an average target price of $159.06.

In other news, CEO Mark Pruzanski sold 50,000 shares of Intercept Pharmaceuticals stock in a transaction that occurred on Friday, November 16th. The shares were sold at an average price of $101.07, for a total transaction of $5,053,500.00. Following the sale, the chief executive officer now owns 589,199 shares in the company, valued at $59,550,342.93. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, major shareholder S.P.A. Genextra sold 750,000 shares of Intercept Pharmaceuticals stock in a transaction that occurred on Thursday, November 29th. The shares were sold at an average price of $105.07, for a total transaction of $78,802,500.00. Following the sale, the insider now owns 6,095,578 shares in the company, valued at approximately $640,462,380.46. The disclosure for this sale can be found here. Insiders have sold 812,130 shares of company stock worth $85,159,685 in the last quarter. Insiders own 4.90% of the company’s stock.

ICPT opened at $110.35 on Thursday. The company has a market cap of $3.29 billion, a PE ratio of -7.67 and a beta of 1.88. Intercept Pharmaceuticals Inc has a 52-week low of $51.76 and a 52-week high of $133.74. The company has a debt-to-equity ratio of 3.83, a quick ratio of 5.98 and a current ratio of 5.98.

ILLEGAL ACTIVITY NOTICE: “Intercept Pharmaceuticals Inc (ICPT) Stake Lifted by Bank of Montreal Can” was originally posted by Community Financial News and is the sole property of of Community Financial News. If you are viewing this piece of content on another website, it was stolen and republished in violation of U.S. and international trademark and copyright law. The original version of this piece of content can be viewed at https://www.com-unik.info/2019/02/14/intercept-pharmaceuticals-inc-icpt-stake-lifted-by-bank-of-montreal-can.html.

Intercept Pharmaceuticals Company Profile

Intercept Pharmaceuticals, Inc is a biopharmaceutical company, which engages in the research, development, and commercialization of novel therapeutics in treating chronic liver diseases. Its product pipeline is OCALIVA which is used for the treatment of primary biliary cholangitis, nonalcoholic steatohepatitis, primary sclerosing cholangitis, and biliary atresia.

Further Reading: Quiet Period Expirations Explained

Want to see what other hedge funds are holding ICPT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Intercept Pharmaceuticals Inc (NASDAQ:ICPT).

Institutional Ownership by Quarter for Intercept Pharmaceuticals (NASDAQ:ICPT)

Receive News & Ratings for Intercept Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit